Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,111 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Oral valganciclovir as preemptive therapy is effective for cytomegalovirus infection in allogeneic hematopoietic stem cell transplant recipients.
Takenaka K, Eto T, Nagafuji K, Kamezaki K, Matsuo Y, Yoshimoto G, Harada N, Yoshida M, Henzan H, Takase K, Miyamoto T, Akashi K, Harada M, Teshima T; for Fukuoka Blood and Marrow Transplant Group (FBMTG). Takenaka K, et al. Among authors: takase k. Int J Hematol. 2009 Mar;89(2):231-237. doi: 10.1007/s12185-008-0249-2. Epub 2009 Jan 17. Int J Hematol. 2009. PMID: 19148587 Clinical Trial.
Quantitation of hematogones at the time of engraftment is a useful prognostic indicator in allogeneic hematopoietic stem cell transplantation.
Shima T, Miyamoto T, Kikushige Y, Mori Y, Kamezaki K, Takase K, Henzan H, Numata A, Ito Y, Takenaka K, Iwasaki H, Kamimura T, Eto T, Nagafuji K, Teshima T, Kato K, Akashi K. Shima T, et al. Among authors: takase k. Blood. 2013 Jan 31;121(5):840-8. doi: 10.1182/blood-2012-02-409607. Epub 2012 Dec 11. Blood. 2013. PMID: 23233661 Free article. Clinical Trial.
Combination of bortezomib, thalidomide, and dexamethasone (VTD) as a consolidation therapy after autologous stem cell transplantation for symptomatic multiple myeloma in Japanese patients.
Takashima S, Miyamoto T, Kadowaki M, Ito Y, Aoki T, Takase K, Shima T, Yoshimoto G, Kato K, Muta T, Shiratsuchi M, Takenaka K, Iwasaki H, Teshima T, Kamimura T, Akashi K. Takashima S, et al. Among authors: takase k. Int J Hematol. 2014 Aug;100(2):159-64. doi: 10.1007/s12185-014-1611-1. Epub 2014 Jun 14. Int J Hematol. 2014. PMID: 24928523
Mogamulizumab Treatment Prior to Allogeneic Hematopoietic Stem Cell Transplantation Induces Severe Acute Graft-versus-Host Disease.
Sugio T, Kato K, Aoki T, Ohta T, Saito N, Yoshida S, Kawano I, Henzan H, Kadowaki M, Takase K, Muta T, Miyawaki K, Yamauchi T, Shima T, Takashima S, Mori Y, Yoshimoto G, Kamezaki K, Takenaka K, Iwasaki H, Ogawa R, Ohno Y, Eto T, Kamimura T, Miyamoto T, Akashi K. Sugio T, et al. Among authors: takase k. Biol Blood Marrow Transplant. 2016 Sep;22(9):1608-1614. doi: 10.1016/j.bbmt.2016.05.017. Epub 2016 May 21. Biol Blood Marrow Transplant. 2016. PMID: 27220263 Free article.
Comparison of cyclosporine and tacrolimus combined with mycophenolate mofetil in prophylaxis for graft-versus-host disease after reduced-intensity umbilical cord blood transplantation.
Miyamoto T, Takashima S, Kato K, Takase K, Yoshimoto G, Yoshida S, Henzan H, Osaki K, Kamimura T, Iwasaki H, Eto T, Teshima T, Nagafuji K, Akashi K. Miyamoto T, et al. Among authors: takase k. Int J Hematol. 2017 Jan;105(1):92-99. doi: 10.1007/s12185-016-2093-0. Epub 2016 Sep 29. Int J Hematol. 2017. PMID: 27686673
Prospective randomization of post-remission therapy comparing autologous peripheral blood stem cell transplantation versus high-dose cytarabine consolidation for acute myelogenous leukemia in first remission.
Miyamoto T, Nagafuji K, Fujisaki T, Uchida N, Matsue K, Henzan H, Ogawa R, Takase K, Aoki T, Hidaka M, Teshima T, Taniguchi S, Akashi K, Harada M; Japan Study Group for Cell Therapy and Transplantation (JSCT). Miyamoto T, et al. Among authors: takase k. Int J Hematol. 2018 Apr;107(4):468-477. doi: 10.1007/s12185-017-2389-8. Epub 2017 Dec 14. Int J Hematol. 2018. PMID: 29243031 Clinical Trial.
Comparison of calcineurin inhibitors in combination with conventional methotrexate, reduced methotrexate, or mycophenolate mofetil for prophylaxis of graft-versus-host disease after umbilical cord blood transplantation.
Yoshida S, Ohno Y, Nagafuji K, Yoshimoto G, Sugio T, Kamimura T, Ohta T, Takase K, Henzan H, Muta T, Iwasaki H, Ogawa R, Eto T, Akashi K, Miyamoto T. Yoshida S, et al. Among authors: takase k. Ann Hematol. 2019 Nov;98(11):2579-2591. doi: 10.1007/s00277-019-03801-z. Epub 2019 Oct 18. Ann Hematol. 2019. PMID: 31628517
1,111 results